Melillo, Giovanni

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 4,593

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 2,798

Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.

Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research

Cancer, Hypoxia, and MetabolismHeterocyclic Compound Synthesis and Bioactivity

Cited by 508

Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1

Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research

Cancer therapeutics and mechanismsCancer, Hypoxia, and Metabolism

Cited by 301

Development of HIF‐1 inhibitors for cancer therapy

Onnis, B., Rapisarda, A., & Melillo, G. (2009) · Journal of Cellular and Molecular Medicine

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 268

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research

PARP inhibition in cancer therapyCancer therapeutics and mechanisms

Cited by 259

HIF-1: A Target For Cancer, Ischemia and Inflammation—Too Good to be True?

Melillo, G. (2004) · Cell Cycle

DNA Repair MechanismsCancer, Hypoxia, and Metabolism

Cited by 247

Targeting hypoxia cell signaling for cancer therapy

Melillo, G. (2007) · Cancer and Metastasis Reviews

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 230

Functional Requirement of the Hypoxia-responsive Element in the Activation of the Inducible Nitric Oxide Synthase Promoter by the Iron Chelator Desferrioxamine

Melillo, G., Taylor, L. S., Brooks, A., Musso, T., Cox, G. W., & Varesio, L. (1997) · Journal of Biological Chemistry

Nitric Oxide and Endothelin EffectsCancer, Hypoxia, and Metabolism

Cited by 201

Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts

Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research

Cancer, Hypoxia, and MetabolismCancer therapeutics and mechanisms

Cited by 187

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 171

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 159

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Kummar, S., Raffeld, M., Juwara, L., Horneffer, Y., Strassberger, A., Allen, D., Steinberg, S. M., Rapisarda, A., Spencer, S. D., Figg, W. D., et al. (2011) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 115

Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1α Expression in an AhR-Independent Fashion

Terzuoli, E., Puppo, M., Rapisarda, A., Uranchimeg, B., Cao, L., Burger, A. M., Ziche, M., & Melillo, G. (2010) · Cancer Research

Cancer, Hypoxia, and MetabolismFlavonoids in Medical Research

Cited by 111

Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells

Calvani, M., Trisciuoglio, D., Bergamaschi, C., Shoemaker, R. H., & Melillo, G. (2008) · Cancer Research

Angiogenesis and VEGF in CancerCancer, Hypoxia, and Metabolism

Cited by 80

Targeting Topoisomerase 1 to inhibit Hypoxia Inducible Factor 1

Rapisarda, A., Shoemaker, R. H., & Melillo, G. (2004) · Cell Cycle

Cancer, Hypoxia, and MetabolismCancer therapeutics and mechanisms

Cited by 41